However, the clinical research on BRAF inhibitors in NSCLC is just beginning and a number of relevant questions remain to be addressed regarding the role of other BRAF inhibitors in NSCLC, the possibility of facing resistance mechanisms to BRAF inhibitors, and the efficacy of other therapeutic strategies for BRAF-mutated NSCLC. Here, BRAF is linked to non-small cell lung carcinoma.